The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Prognostic significance of nutritional and inflammatory markers in patients with unresectable pancreatic ductal adenocarcinoma treated with chemotherapy.
 
Ryosuke Kobiyama
No Relationships to Disclose
 
Isaku Yoshioka
No Relationships to Disclose
 
Takayuki Ando
No Relationships to Disclose
 
Shinya Kajiura
No Relationships to Disclose
 
Kazuto Shibuya
No Relationships to Disclose
 
Shinichi Sekine
No Relationships to Disclose
 
Katsuhisa Hirano
No Relationships to Disclose
 
Hayato Baba
No Relationships to Disclose
 
Mie Arai
No Relationships to Disclose
 
Kenta Sukegawa
No Relationships to Disclose
 
Toru Watanabe
No Relationships to Disclose
 
Isaya Hashimoto
No Relationships to Disclose
 
Shozo Hojo
No Relationships to Disclose
 
Tomoyuki Okumura
No Relationships to Disclose
 
Takuya Nagata
No Relationships to Disclose
 
Kenta Murotani
No Relationships to Disclose
 
Ichiro Yasuda
No Relationships to Disclose
 
Tsutomu Fujii
Honoraria - Asahi Kasei; Chugai Pharma; Covidien/Medtronic; CSL Behring; EA Pharma; Japan Blood Products Organization; Johnson & Johnson; Kaken Pharmaceutical; Lilly; Miyarisan pharmaceutical; MSD; Novelpharm; Otsuka; Taiho Pharmaceutical; TERUMO; Tsumura & Co.
Research Funding - Asahi Kasei (Inst); Astellas Pharma (Inst); Central Medical (Inst); Chugai Pharma (Inst); Covidien/Medtronic (Inst); CSL Behring (Inst); Daiichi Sankyo (Inst); EA Pharma (Inst); Eisai (Inst); Johnson & Johnson (Inst); Kaken Pharmaceutical (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Miyarisan pharmaceutical (Inst); Nihonkayaku (Inst); Otsuka (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); TERUMO (Inst); Tsumura & Co. (Inst)